MX2009000359A - Metodos paratratar y limitar trastornos fibroticos y queloides. - Google Patents

Metodos paratratar y limitar trastornos fibroticos y queloides.

Info

Publication number
MX2009000359A
MX2009000359A MX2009000359A MX2009000359A MX2009000359A MX 2009000359 A MX2009000359 A MX 2009000359A MX 2009000359 A MX2009000359 A MX 2009000359A MX 2009000359 A MX2009000359 A MX 2009000359A MX 2009000359 A MX2009000359 A MX 2009000359A
Authority
MX
Mexico
Prior art keywords
keloids
treating
fibrotic disorders
methods
limiting
Prior art date
Application number
MX2009000359A
Other languages
English (en)
Spanish (es)
Inventor
Luciana Biagini Lopes
Elizabeth J Furnish
Charles Robert Flynn
Padmini Komalavilas
Alyssa Panitch
Colleen M Brophy
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Publication of MX2009000359A publication Critical patent/MX2009000359A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2009000359A 2006-07-12 2007-07-10 Metodos paratratar y limitar trastornos fibroticos y queloides. MX2009000359A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83027906P 2006-07-12 2006-07-12
US84904106P 2006-10-02 2006-10-02
PCT/US2007/073144 WO2008008772A2 (en) 2006-07-12 2007-07-10 Methods for treating and limiting fibrotic disorders and keloids

Publications (1)

Publication Number Publication Date
MX2009000359A true MX2009000359A (es) 2009-05-08

Family

ID=38924094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000359A MX2009000359A (es) 2006-07-12 2007-07-10 Metodos paratratar y limitar trastornos fibroticos y queloides.

Country Status (13)

Country Link
US (1) US20110028398A1 (cg-RX-API-DMAC7.html)
EP (1) EP2051727A4 (cg-RX-API-DMAC7.html)
JP (1) JP5048772B2 (cg-RX-API-DMAC7.html)
KR (1) KR101267217B1 (cg-RX-API-DMAC7.html)
AU (1) AU2007272578B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714383A2 (cg-RX-API-DMAC7.html)
CA (1) CA2657263A1 (cg-RX-API-DMAC7.html)
CR (1) CR10552A (cg-RX-API-DMAC7.html)
DO (1) DOP2009000005A (cg-RX-API-DMAC7.html)
MX (1) MX2009000359A (cg-RX-API-DMAC7.html)
NZ (1) NZ574717A (cg-RX-API-DMAC7.html)
SG (1) SG173369A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008008772A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2155228T3 (da) 2007-01-10 2014-07-07 Purdue Research Foundation Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor
WO2009021137A2 (en) 2007-08-07 2009-02-12 Purdue Research Foundation Kinase inhibitors and uses thereof
EP2334319B1 (en) * 2008-08-25 2017-12-06 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to ctgf
ES2685505T3 (es) 2008-12-10 2018-10-09 Purdue Research Foundation Inhibidor de cinasas basado en péptidos de permeación celular
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2013134177A1 (en) * 2012-03-05 2013-09-12 Capstone Therapeutics Corp. Methods and compositions for improving spinal surgery outcomes
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
KR102166543B1 (ko) * 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
WO2016014621A1 (en) * 2014-07-22 2016-01-28 The Regents Of The University Of California Endosomal escape domains for delivery of macromolecules into cells
KR101667900B1 (ko) * 2016-01-15 2016-10-21 테고사이언스 (주) 켈로이드성 피부 또는 켈로이드 흉터 진단용 바이오마커 단백질 및 이의 이용

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280038A (en) * 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
US5985635A (en) * 1996-11-15 1999-11-16 Incyte Pharmaceuticals, Inc. Nucleic acids encoding novel human serine/threonine protein kinases
US7556722B2 (en) * 1996-11-22 2009-07-07 Metzger Hubert F Electroplating apparatus
US6475490B1 (en) * 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AU2001249214A1 (en) * 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
ES2432225T3 (es) * 2001-08-23 2013-12-02 Arizona Board Of Regents Reactivos y procedimientos para terapias del músculo liso
AU2003260668A1 (en) * 2002-04-01 2003-10-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
ATE455553T1 (de) * 2003-02-21 2010-02-15 Univ Arizona Verwendung von hsp20 zur förderung der wundheilung und/oder zur reduzierung der narbenbildung
WO2005037236A2 (en) * 2003-10-17 2005-04-28 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor
JP2009033589A (ja) * 2007-07-30 2009-02-12 Ricoh Co Ltd 画像形成装置、プログラムおよび記録媒体

Also Published As

Publication number Publication date
BRPI0714383A2 (pt) 2013-04-30
SG173369A1 (en) 2011-08-29
EP2051727A2 (en) 2009-04-29
WO2008008772A3 (en) 2008-10-16
WO2008008772A2 (en) 2008-01-17
JP2009543800A (ja) 2009-12-10
EP2051727A4 (en) 2012-03-14
NZ574717A (en) 2011-11-25
US20110028398A1 (en) 2011-02-03
JP5048772B2 (ja) 2012-10-17
KR20090023685A (ko) 2009-03-05
AU2007272578A1 (en) 2008-01-17
DOP2009000005A (es) 2009-04-30
KR101267217B1 (ko) 2013-05-31
AU2007272578B2 (en) 2012-11-08
CR10552A (es) 2009-05-04
CA2657263A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
MX2009000359A (es) Metodos paratratar y limitar trastornos fibroticos y queloides.
MX2010009724A (es) Procedimientos de tratamiento del dolor inflamatorio-.
MX2010007564A (es) Composiciones de limpieza y/o tratamiento.
PH12012502380B1 (en) Methods of treatment of pancreatic cancer
WO2011090741A3 (en) TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
WO2011022606A3 (en) Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
MX339820B (es) Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1.
IN2012DN02018A (cg-RX-API-DMAC7.html)
PH12012500916B1 (en) Treatments for gastrointestinal disorders
WO2008137867A3 (en) Compositions comprising mir34 therapeutic agents for treating cancer
WO2011103528A3 (en) Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
IL206563A (en) A preparation or drug containing a suspension of blood cells that contain asparaginase for use in the treatment of pancreatic cancer
WO2011082409A3 (en) Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
WO2010102058A3 (en) Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
WO2011079263A3 (en) Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
WO2011084455A3 (en) Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
MX2011013577A (es) Composiciones y metodos para tratar esclerosis lateral amiotrofica.
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
WO2010148065A3 (en) Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
MX2009005114A (es) Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
EP2633052A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH THE INTERFERON 1-RELATED DEVELOPMENT REGULATOR (IFRD1) BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPTION PRODUCT OF IFRD1
WO2012009402A3 (en) Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
WO2012009347A3 (en) Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration